Zhengda Tianqing broke out!

Recently, CP Tianqing Pharmaceutical Group's product line has been frequently updated: colorectal cancer drug trefluridine tepipyrimidine tablets have been approved for marketing, class 1 new drugs TQB2916 and TQB2868 have successively applied for INDs, and 210 million yuan has been introduced to introduce long-acting baiyao.
.
.
this year Since then, the company has been approved for the listing of 8 varieties, 19 varieties have been reviewed, and 13 new drugs of Category 1 have been declared IND
.

At present, the company has already reviewed 47 varieties (19 are the first ones), 13 varieties are waiting to be collected; 16 generic drug listing applications are under review, and 11 sprints are for the first imitation

An explosion of innovative drugs! 49 new class 1 drugs, 6 class 2 biological drugs

An explosion of innovative drugs! 49 new class 1 drugs, 6 class 2 biological drugs

Entering September, CP Tianqing Pharmaceutical Group's two new Class 1 drugs, TQB2916 injection and TQB2868 injection, continued to apply for IND
.

Since the beginning of this year, the company has applied for IND for 13 new drugs in category 1 category

With the rise of the industry's innovation and transformation wave, CP Tianqing Pharmaceutical Group has laid out a huge pipeline of innovative drugs in a low-key manner
.

After years of intensive research and development of innovative drugs, the company's product line will usher in an intensive harvest period

Anlotinib hydrochloride capsules and magnesium isoglycyrrhizinate injection are Class 1 chemical drugs of Zhengda Tianqing Pharmaceutical Group, and the PD-1 monoclonal antibody Paimrizumab injection developed in cooperation with Kangfang Biological is the company’s first 1 Class biological drugs
.

Magnesium isoglycyrrhizinate has been on the market for more than ten years and has created huge profits for the company; Anlotinib has won 4 indications, the first-line differentiated thyroid cancer indication NDA is under review, and the second-line and above soft tissue sarcoma indications are in the phase III clinical stage; Amplizumab has been approved for the treatment of Hodgkin’s lymphoma, and the NDA indications for non-small cell lung cancer and nasopharyngeal carcinoma are under review
.

According to data from Meinenet, in addition to commercialized products, CP Tianqing Pharmaceutical Group has 49 category 1 innovative drugs that are in the clinical stage or declared for clinical use
.

Among them, there are 41 small-molecule chemical drugs and 8 large-molecule biological drugs, covering diseases such as tumors, liver diseases, metabolism, and asthma.

Zhengda Tianqing Pharmaceutical Group is developing a Class 1 innovative drug

Source: China Drug Clinical Trial Publicity Library of Meinenet

From the perspective of R&D progress, TQB2450 injection (PD-L1 monoclonal antibody) and TQ-B3139 capsules (ALK inhibitor) are in phase III clinical phase; 6 innovative drugs are in phase II clinical phase, including TQ-B3525 tablets (PI3K inhibitor) agent), TQ-F3083 capsules (DPP-4 inhibitor), TQB3616 capsules (CDK4 / 6 inhibitor), TQA3526 sheet (FXR agonist), AL2846 capsules (the TKI) and the like
.

It is worth noting that among the 49 innovative drugs being developed by CP Tianqing Pharmaceutical Group, there are as many as 34 innovative drugs in the oncology field
.

In recent years, the scale of the domestic anti-tumor drug market has continued to rise.

Zhengda Tianqing Pharmaceutical Group is researching biosimilar drugs

Source: China Drug Clinical Trial Publicity Library of Meinenet

In addition to Class 1 innovative drugs, CP Tianqing Pharmaceutical Group has also deployed 6 biosimilar drugs, of which bevacizumab and adalimumab have declared NDA, rituximab, trastuzumab, and Pertuzumab Rizumab is in the phase III clinical stage and is expected to be approved for marketing in the next three years
.

In the future, with the successive launch of innovative drugs under research and increased sales, the proportion of innovative drugs in CP Tianqing Pharmaceutical Group’s revenue will gradually increase, and the company’s product structure will be further optimized, gradually transitioning from imitation to innovation, and consolidating the industry Leading position
.

Won 8 heavy varieties, 47 over-reviewed varieties are eye-catching

Won 8 heavy varieties, 47 over-reviewed varieties are eye-catching

On September 13, the NMPA official website showed that Chia Tai Tianqing Pharmaceutical Group was approved to market with the imitation of three types of trifluridine tepipyrimidine tablets, which were deemed to have passed the consistency evaluation
.

Trifluridine tepipyrimidine tablet is an oral compound preparation composed of trefluridine (FTD) and tepipyridine (TPI) in a molar ratio of 1:0.

As the king of the first imitation in China, CP Tianqing Pharmaceutical Group has been focusing on the layout of the first imitation and high-tech barrier generic drugs
.

Since the beginning of this year, Chia Tai Tianqing Pharmaceutical Group has approved 8 products for listing
.

Among them, lenvatinib mesylate capsules and vothiaxetine hydrobromide tablets are the first domestic imitations, and aprepitant capsules, trifluridine tepipyrimidine tablets, and esomeprazole magnesium enteric-coated capsules are The second domestic manufacturer, the third domestic manufacturer of Enpagliflozin tablets, and the fourth domestic manufacturer of sunitinib malate capsules

Generic drugs approved for listing by Chia Tai Tianqing Pharmaceutical Group since 2021

Source: Meinenet MED2.
0 Chinese Drug Evaluation Database

Trifluridine tepipyrimidine tablets are also the 19th variety reviewed by CP Tianqing Pharmaceutical Group this year
.

Up to now, CP Tianqing Pharmaceutical Group has passed/deemedly passed the consistency evaluation of 47 varieties (67 product regulations), of which 19 varieties were the first in China to have passed the evaluation
.

47 varieties cover 10 treatment categories, of which, 17 varieties of anti-tumor and immunomodulators have been reviewed, and 10 varieties of digestive system and metabolic drugs have been reviewed

11 varieties grab the first imitation! 13 varieties ready for collection

11 varieties grab the first imitation! 13 varieties ready for collection

New registration classification of generic drugs under review by Zhengda Tianqing Pharmaceutical Group

Source: Meinenet MED2.
0 Chinese Drug Evaluation Database

According to data from Meinenet, there are 16 generic drugs under review by CP Tianqing Pharmaceutical Group under the new registration classification, which will be deemed to have passed the consistency evaluation after being approved for production
.
From the treatment field, there are 4 varieties of drugs for the respiratory system, 3 varieties each for anti-tumor and immunomodulators, anti-infective drugs for systemic use, and digestive system and metabolic drugs
.
It is worth mentioning that the 4 respiratory medications are all inhalants with high technical barriers
.

The 11 varieties have not yet been approved for the listing of generic drugs in the domestic market
.
Among them, methacholine for inhalation, arformoterol tartrate atomized inhalation solution, dexlansoprazole enteric-coated capsules, umelonium bromide vilanterol powder inhalation, fluticasone furoate vilanterol powder inhalation Six varieties, including polymyxin E sodium methanesulfonate for injection, were first or exclusively applied for listing by Zhengda Tianqing Pharmaceutical Group, and they are likely to win the first imitation
.

Among the five batches of centralized procurement carried out by the country, CP Tianqing Pharmaceutical Group has won a total of 19 varieties, 13 of which are newly approved varieties
.
It is worth noting that 17 of the approved varieties of CP Tianqing Pharmaceutical Group have not yet been included in the collection
.
Among them, there are 13 varieties that meet the conditions of centralized procurement, which are expected to be included in the next batch of centralized procurement
.

Zhengda Tianqing Pharmaceutical Group is not included in the situation of centralized procurement varieties

Source: Meinenet MED2.
0 Chinese Drug Evaluation Database

Seven of the 13 varieties are newly approved varieties.
Except for Dasatinib tablets, the market for other varieties is almost blank.
If it is included in the centralized procurement and won the bid, it is expected to achieve rapid volume, save sales costs, earn import substitution, and small profits but quick turnover.
Money, and provide financial support for the company’s innovation and transformation
.

Data source: Mi Nei.
com database, company announcement

Note: The statistics are as of September 15, if there are any omissions, please correct me!